Identification of Resistance Determinants for a Promising Antileishmanial Oxaborole Series

Current treatment options for visceral leishmaniasis have several drawbacks, and clinicians are confronted with an increasing number of treatment failures. To overcome this, the Drugs for Neglected Diseases initiative (DNDi) has invested in the development of novel antileishmanial leads, including a...

Descripción completa

Detalles Bibliográficos
Autores principales: Van den Kerkhof, Magali, Leprohon, Philippe, Mabille, Dorien, Hendrickx, Sarah, Tulloch, Lindsay B., Wall, Richard J., Wyllie, Susan, Chatelain, Eric, Mowbray, Charles E., Braillard, Stéphanie, Ouellette, Marc, Maes, Louis, Caljon, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305145/
https://www.ncbi.nlm.nih.gov/pubmed/34210040
http://dx.doi.org/10.3390/microorganisms9071408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305145/
https://www.ncbi.nlm.nih.gov/pubmed/34210040
http://dx.doi.org/10.3390/microorganisms9071408

Ejemplares similares